Novo Nordisk Wins Patent Case for Semaglutide in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Patent Protection Victory: The Supreme People's Court of China upheld the validity of the semaglutide compound patent, marking a significant victory for Novo Nordisk in intellectual property protection, which enhances the company's confidence and growth potential in the Chinese market.
- Strengthened Government Support: This ruling is described by Novo Nordisk's CEO as a firm government endorsement of medical innovation, which is expected to motivate more foreign companies to pursue sustainable development and innovative drug research in China.
- Market Impact Assessment: Although Novo Nordisk anticipates that the expiration of the semaglutide patent in certain countries will negatively impact global sales growth in 2026 by a low single-digit percentage, this ruling does not alter the company's previous sales forecasts, indicating market stability.
- Industry Position Consolidation: As one of Novo Nordisk's flagship products, semaglutide has achieved approximately 38 million patient-years of use globally, further solidifying the company's leadership position in diabetes and obesity treatment.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 51.220
Low
47.00
Averages
57.37
High
70.00
Current: 51.220
Low
47.00
Averages
57.37
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
